0001534120-26-000033
SEC filingAvalo reported a wider operating loss and increased cash outflow in Q1 FY2026, reflecting intentional investment to advance abdakibart into registrational Phase 3 following positive LOTUS trial results — a strategic front-loading of spend, not operational deterioration.
Operating income for Q1 FY2026 was -$20.9M, compared to -$14.7M in Q1 FY2025 — a 42.5% year-over-year decline in magnitude. Net income was -$19.6M, versus -$13.1M in the prior-year quarter, representing a 49.3% increase in loss magnitude. These results reflect sustained investment in abdakibart development, particularly following the positive Phase 2 LOTUS trial results in hidradenitis suppurativa. Management has stated that it expects future research and development expenses to increase over time as it prepares and advances abdakibart into a registrational Phase 3 program — confirming that the current financial profile is intentional and forward-looking.
Diluted EPS was -$0.98 for Q1 FY2026, an improvement from -$1.25 in Q1 FY2025. This 21.6% improvement in EPS is attributable solely to an increase in the weighted-average diluted shares outstanding — a structural outcome of prior equity issuances and RSU settlements — and does not reflect any improvement in profitability or operational efficiency. The larger net loss combined with higher share count underscores that EPS movement in this context is decoupled from underlying performance trends.
Avalo’s financial trajectory remains anchored in its clinical strategy: advancing abdakibart toward registration. Management explicitly states that it expects future cash used in operating activities to increase over time as a result of its intention to advance abdakibart into a registrational Phase 3 program. This expectation — coupled with the acknowledgment that the company has incurred significant operating losses and negative cash flows from operations since inception — frames the current quarter not as a deviation, but as a predictable inflection point in the company’s development lifecycle. Liquidity remains focused on funding abdakibart development and associated organizational infrastructure, with no material changes to capital allocation priorities disclosed in this filing.